Enlivex said it secured $21 million in debt financing from New York asset manager The Lind Partners to buy additional tokens tied to the Rain prediction market. The financing funded the exercise of an option to acquire roughly 3 billion RAIN tokens at a 62% discount, a purchase that cost about $10 million. The company also extended its option to acquire another 272.1 billion RAIN tokens at the same price through December 2027.
Enlivex’s executive chair, Shai Novik, said the deal advances the company’s prediction-markets treasury plan and provides substantial capital to support both its operating strategy and the RAIN token purchases.
The biotech firm, which develops cell-therapy treatments for knee osteoarthritis, joins a number of non-crypto public companies that have added cryptocurrency holdings to bolster balance sheets and attract a broader set of investors. Separately, Enlivex approved a $20 million share buyback program aimed at enhancing shareholder value.
RAIN tokens are linked to Rain’s decentralized prediction market, which levies a 2.5% fee on activity; those fees are automatically used to buy back and burn RAIN, affecting token supply dynamics. Following Enlivex’s announcement, RAIN briefly jumped about 7% to $0.009 before settling near $0.0088, roughly flat over 24 hours with a 0.3% gain, according to CoinGecko. Enlivex shares (ENVL) were largely unchanged, closing down 0.9% at $1.10 and later trading up about 4.5% after hours at $1.15.
Rain runs on the Ethereum Layer-2 Arbitrum network and ranks among the top 10 prediction-market platforms by total value locked and fees, per DeFiLlama. The prediction-market sector has expanded rapidly: trading volumes rose more than 1,200% to $23.3 billion between February 2025 and February 2026. The market remains concentrated, with Kalshi and Polymarket accounting for over 80% of trading volumes.